LifeSci Venture Partners
LifeSci is a private equity firm that invests in life science based startups.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed LifeSci Venture Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
LifeSci is a private equity firm that invests in life science based startups.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2022 | Beta Bionics | Series C | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 11/2020 | Viracta Therapeutics | Series E | 0 |
| 9/2020 | Orasis Pharmaceuticals | Series C | 0 |
| 3/2021 | Iridia | Series B | 0 |
| 9/2017 | Engage Therapeutics | Series A | 23.6M |
| 2/2021 | Viracta Therapeutics | Post-IPO Equity | 65M |
| 1/2021 | Mana Therapeutics | Series A | 35M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 4/2020 | Erasca | Series B | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 12/2017 | Allakos | Series B | 100M |
| 3/2019 | Erasca | Series A | 0 |
| 6/2018 | Orasis Pharmaceuticals | Series B | 13M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 3/2021 | Omega Therapeutics | Series C | 126M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 11/2021 | Clade Therapeutics | Series A | 0 |
| 3/2019 | Biolinq | Series A | 4.8M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 11/2017 | Biolinq | Series A | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 3/2021 | Caribou Biosciences | Series C | 115M |
| 3/2021 | EGenesis | Series C | 0 |
| 5/2019 | Cala Health | Series C | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 1/2019 | Beta Bionics | Series B | 63M |
| 8/2020 | Science 37 | Venture Round | 0 |
| 1/2019 | Attune Pharmaceuticals | Series B | 23M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 6/2021 | RayzeBio | Series C | 108M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 11/2021 | Clade Therapeutics | Series A | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 6/2021 | RayzeBio | Series C | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 3/2021 | Omega Therapeutics | Series C | 0 |
| 3/2021 | Pyxis Oncology | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
